Anti-Aging And Aesthetic Medicine: The Silent Rise Of This Multibillion Dollar Industry – Forbes

Aging is an inevitable phenomenon. Over the last 40 years, there has been an incredible focus on the aesthetics of aging, particularly with an emphasis on cosmetic anti-aging therapies. These efforts have faced their share of controversy, as scientists continue to debunk false advertising and anti-aging therapies that are not backed by evidence-based medicine. Nonetheless, regardless of the controversy, an entire industry and therapeutic cosmos has silently grown around the promise of aesthetic rejuvenation.

The anti-aging market is positioned to reach $271 billion by 2024. Studies report that anti-wrinkle products alone will reach $12.8 billion dollars in market share by 2027. The American Society of Plastic Surgeons also noted the growth in rates of cosmetic surgery procedures from the year 2000 to 2018: breast augmentation procedures increased by 48%, abdominoplasty (tummy tuck) procedures were up by 107%, and most notably, the use of Botox injections increased by an astounding 845%. According to this report, there has been an overall increase by 163% in the number of total cosmetic procedures from the year 2000 to 2018. Indeed, these startling figures not only indicate the immense value of this market, but also point to an industry that shows no signs of slowing down.

Plastic surgeon marking the skin for surgery.

Congruently, healthcare providers and practices have also benefited from this immense growth. An Allegran/BSM Medical Aesthetics Database study found that revenues have steadily increased for medical aesthetic and dermatology practices/clinics across the USA, due in large part to providers offering more varied aesthetic services and hiring staff dedicated solely to this business. Industry growth is likely also due to the fact that the practice of cosmetic medicine, which was once a domain reserved solely for dermatologists and plastic surgeons, is now being practiced by other specialists; in a 2014 survey, it was reported that upto 22% of family physicians are now providing some form of cosmetic and aesthetic medicine in their practices. Thus, this phenomenon is permeating all aspects of the modern healthcare practice.

However, as with any multibillion dollar industry that undergoes dramatic and exponential growth, the rapid rise of the anti-aging market has caused controversy. In 2008, a group of 51 scientists published a groundbreaking scientific report, raising concerns around the lack of scientific and evidence-based medicine behind some anti-aging treatments. More recently, the U.S. Food and Drug Administration is similarly attempting to address concerns in this area, warning consumers about sham products and cosmetic myths. Fortunately, there is a growing scientific community that is focused on educating the public about evidence-based anti-aging strategies and techniques, so that consumers are well informed and aware of genuine, scientifically proven therapies.

Variety of skin and body care products.

Ultimately, however, in order to responsibly grow this industry, certain parameters need to be maintained. As with any other medical procedure or pharmaceutical product, regulators and practitioners alike need to be increasingly wary of new or untested products that claim to have anti-aging effects without significant evidence-based backing. The same should be said about the practice of actually administering these products to patients. Anti-aging therapy should be considered a form of medical practice, and as with any form of medicine, it is imperative that governing bodies place strict standards of competency, training, and technical pre-requisites prior to allowing practitioners to administer these therapies on their own accord. These steps will certainly be necessary in the coming decades, as there is no doubt that public demand will continue to fuel this phenomenon. However, maintaining close oversight and a strict emphasis on evidenced-based medicine, is the only way to ensure the safe, sustainable, and patient-centered growth of this robust industry.

More:

Anti-Aging And Aesthetic Medicine: The Silent Rise Of This Multibillion Dollar Industry - Forbes

Sports Medicine Brand Gsport Owes Their Success to the Quality of Their Products and the Quality of Life They Provide for Employees – Yahoo Finance

FORT LAUDERDALE, Fla., Jan. 29, 2020 /PRNewswire/ --Predictions for the Sports Medicine market look increasingly optimistic with sales forecasts over $300 Million in the next five years. While this boom leaves room for competition among existing companies, many brands vying for a place in this rapidly expanding frontier may find product quality is one factor in their long-term market success.

Fueled by predictions that the North American market will take the lead in the coming sports-medicine boom, Chinese company Gsport expands to sell its products in the United States for the first time since the company's inception in 2003. Founded in China's Zhejiang Province, Gsport quickly rose to the top of the sports medicine market because of its unique advantage for quality control. Controlling all aspects of production, from brainstorm to assembly line, conveniently located in one manufacturing facility, gave Gsport the edge over its competition when it came to product quality.

But the real secret to their success might be Gsport's "Human-Oriented" corporate culture. The company's core belief in integrity and treating their workers fairly has paid off by way of productivity and scientific development. Gsport is considered an "industry trendsetter" when it comes to how they treat their employees, with a Worker's Fund available for sick or injured employees. While on the job employees have access to world-class break rooms with fully equipped gymnasium, as well as tennis and basketball courts, and ping-pong tables. For employees who commute in to the Zhejiang facility, often living far from family in more rural areas, Gsport provides a travel fund and vacation time so that workers can travel home.

Happy workers seem to create better products, keeping Gsport in the business of supplying the highest standard of sports medicine products for almost 20 years. The company's most popular products include Cohesive Cold Bandages and Kinesiology Tape, all developed with the highest level of rigorous testing.

Kinesiology tape is a huge factor in the boom in sport's medicine. With athletes from around the world wearing kinesiology tapes while out on the field, more consumers are becoming aware of this safe and effective product.

Gsport's kinesiology tape works by gently lifting the skin to allow for greater blood flow to affected muscles during and after physical activity. More blood and more oxygen reaching muscles means less damage from muscle use. Gsport's kinesiology tape does not stick to hair, making removal easy and painless.

From product quality to quality of life, Gsport's recipe for success has brought them international recognition and an ever-expanding customer base.

Please direct inquiries to:Noel Ramune 954-399-2207233286@email4pr.com

View original content:http://www.prnewswire.com/news-releases/sports-medicine-brand-gsport-owes-their-success-to-the-quality-of-their-products-and-the-quality-of-life-they-provide-for-employees-300994896.html

SOURCE Gsport

Read the original here:

Sports Medicine Brand Gsport Owes Their Success to the Quality of Their Products and the Quality of Life They Provide for Employees - Yahoo Finance

Decibel Therapeutics Announces Strategic Research Focus on Regenerative Medicine for the Inner Ear – BioSpace

BOSTON--(BUSINESS WIRE)-- Decibel Therapeutics, a development-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, today announced a new strategic research focus on regenerative medicine approaches for the inner ear. The company is also announcing a collaboration and option agreement that gives Decibel exclusive access to novel compounds targeting proteins in a critical regenerative pathway.

Decibels research focus on regeneration will be powered by the companys research and translation platform. The company has built one of the most sophisticated single cell genomics and bioinformatics platforms in the industry to identify and validate targets. Decibel has also developed unique insights into regulatory pathways and inner ear delivery mechanisms that together enable precise control over gene expression in the inner ear and differentiate its AAV-based gene therapy programs.

Our deep understanding of the biology of the inner ear and our advanced technological capabilities come together to create a powerful platform for regenerative medicine therapies for hearing and balance disorders, said Laurence Reid, Ph.D., acting CEO of Decibel. We see an exciting opportunity to leverage this platform to address a broad range of hearing and balance disorders that severely compromise quality of life for hundreds of millions of people around the world.

The first program in Decibels regeneration portfolio aims to restore balance function using an AAV-based gene therapy (DB-201), which utilizes a cell-specific promoter to selectively deliver a regeneration-promoting gene to target cells. In collaboration with Regeneron Pharmaceuticals, Decibel will initially evaluate DB-201 as a treatment for bilateral vestibulopathy, a debilitating condition that significantly impairs balance, mobility, and stability of vision. Ultimately, this program may have applicability in a broad range of age-related balance disorders. There are currently no approved medicines to restore balance. Decibel expects to initiate IND-enabling experiments for this program in the first half of 2020.

Decibel is also pursuing novel targets for the regeneration of critical cells in both the vestibule and cochlea of the inner ear; these targets may be addressable by gene therapy or other therapeutic modalities. As a key component of that program, Decibel today announced an exclusive worldwide option agreement with The Rockefeller University, which has discovered a novel series of small-molecule LATS inhibitors. LATS kinases are a core component of the Hippo signaling pathway, which plays a key role in regulating both tissue regeneration and the proliferation of cells in the inner ear that are crucial to hearing and balance. The agreement gives Decibel an exclusive option to license this series of compounds across all therapeutic areas.

The agreement also establishes a research collaboration between Decibel and A. James Hudspeth, M.D., Ph.D., the F.M. Kirby Professor at The Rockefeller University and the director of the F.M. Kirby Center for Sensory Neuroscience. Dr. Hudspeth is a world-renowned neuroscientist, a member of the National Academy of Sciences and the American Academy of Arts and Sciences, and a Howard Hughes Medical Institute investigator. Dr. Hudspeth has been the recipient of numerous prestigious awards, including the 2018 Kavli Prize in Neuroscience.

Rockefeller scientists are at the leading edge of discovery, and we are excited to see the work of Dr. Hudspeth move forward in partnership with Decibel, said Jeanne Farrell, Ph.D., associate vice president for technology advancement at The Rockefeller University. The ambitious pursuit of harnessing the power of regenerative medicine to create a new option for patients with hearing loss could transform how we address this unmet medical need in the future.

In parallel with its new research focus on regenerative strategies, Decibel will continue to advance key priority preclinical and clinical programs. DB-020, the companys clinical-stage candidate designed to prevent hearing damage in people receiving cisplatin chemotherapy, is in an ongoing Phase 1b trial. Decibel will also continue to progress DB-OTO, a gene therapy for the treatment of genetic congenital deafness, which is being developed in partnership with Regeneron Pharmaceuticals. The DB-OTO program aims to restore hearing to people born with profound hearing loss due to a mutation in the otoferlin gene and is expected to progress to clinical trials in 2021.

To support the new research focus, Decibel is restructuring its employee base and discontinuing some early-stage discovery programs.

About Decibel Therapeutics, Inc. Decibel Therapeutics, a development-stage biotechnology company, has established the worlds first comprehensive drug discovery, development, and translational research platform for hearing loss and balance disorders. Decibel is advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all. Decibels lead therapeutic candidate, DB-020, is being investigated for the prevention of ototoxicity associated with cisplatin chemotherapy. For more information about Decibel Therapeutics, please visit decibeltx.com or follow @DecibelTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200129005162/en/

Visit link:

Decibel Therapeutics Announces Strategic Research Focus on Regenerative Medicine for the Inner Ear - BioSpace

Precision Medicine in Primary Care: Bespoke. Genetic and Genomic. And Maybe Not Ready. – Managed Care magazine

Say precision medicine and people think of personalized cancer treatment. But this innovation has already begun to revolutionize primary care tooeven though the jury is still out, in many cases, on whether it makes a clear difference in outcomes.

Just what precision (alias personalized) medicine is isnt always spelled out precisely. But usually it is discussed as prevention or treatment that takes into account individual differences among patients, most often genetic differences. Some people expand the concept to consider individual differences in environment and lifestyle.

In adult primary care, two subsets of precision medicine have attracted the most attention recently: predictive genetic testing and pharmacogenomics.

Predictive genetic testing is what it sounds like: A genetic test that forecasts a persons chance of getting a disease. The term is also applied to germline genetic tests that provide some indication of the predisposition being passed down to offspring. Proponents see predictive genetic testing for certain inherited conditions as a way to unearth risks in people who can then get early treatment or take preventive steps to head off serious and possibly costly conditions. Actor Angelina Jolie put BRCA testing as a predictive genetic test into the public consciousness with her announcement in 2013 that she underwent a double mastectomy after testing positive for a BRCA mutation.

Pharmacogenomics studies show how a persons genes can affect his or her response to medications. Ideally, pharmacogenomic (sometimes called pharmacogenetic) results could end some of the trial and error with drugs and help providers and patients choose the most effective drug right off the bat.

Where federal dollars are concerned, precision medicine has already stepped out of the cancer box. In 2015, President Barack Obama committed $215 million to precision medicine research, including a genomic study of more than a million Americans to extend precision medicine from cancer to other diseases. A year later, the 21st Century Cures Act expanded this funding to $1.5 billion over the next 10 years.

Aided by a multibillion-dollar genomic testing industry, some providers have started testing precision medicine beyond oncology. In 2018, Geisinger Health System in central Pennsylvania made a splash by announcing that it would add DNA sequencing to routine primary care. A small number of other hospitals are starting to monetize these tests. In August 2019, STAT reported that a handful of academic medical centers, including Brigham and Womens Hospital and the Mayo Clinic, have started elective genome sequencing clinics for generally healthy patients willing to pay hundreds, sometimes thousands of dollars in cash for a genetic workup.

Skeptics see carts preceding horses; solid evidence that routine genetic testing results in better outcomes is lacking. As one genome-sequencing clinic leader conceded in the STAT article, such testing can lead to expensive follow-up testing. Not surprisingly, payers have been reluctant to cover sequencing tests of various kinds.

Regulators have breathed life into some kinds of testing and poured cold water on others. Last year, 23andMe was the first testing company to get FDA approval to market a direct-to-consumer genetic test for three (of the more than 1,000 known) BRCA gene mutations linked to increased risk of breast, ovarian, and prostate cancer. But in April 2019, the agency issued a warning letter to Inova Health System in Northern Virginia to stop marketing pharmacogenomics tests it claimed could predict patients responses to antidepressants, opioids, and other drugs. The FDA said it was unaware of data to support these claims.

A survey published two years ago in Clinical Pharmacology and Therapeutics found that clopidogrel, a blood thinner, was the medication most commonly tested for a druggene interaction, followed by simvastatin and warfarin. Nearly 40 academic medical centers and community health systems testing ways to implement pharmacogenomics in clinical practice were surveyed.

Some evidence suggests that traditional screening methods may not identify everyone at risk for certain inherited conditions. In a study published in Science three years ago, researchers at Geisinger and Regeneron (which manufactures Praluent, a drug used to treat familial hypercholesterolemia) found that only about one in four people carrying the familial hypercholesterolemia gene variant met the Dutch Lipid Clinic Network criteria (widely used diagnostic criteria) for genetic testing. Still, evidence for the clinical utility of many pharmacogenomic or predictive genetic tests is pretty scanty at this point.

Right now, for the average primary care provider, there are a relatively limited number of situations where pharmacogenomic testing is clearly beneficial to outcomes in a way thats dramatic, says Greg Feero, MD, a faculty member at Maine Dartmouth Family Medicine Residency and a former senior advisor to the director of the NIHs genomics research division.

For predictive genetic testing, there are a few notable exceptionshereditary breast and ovarian cancer, Lynch syndrome, and familial hypercholesterolemiaif certain criteria such as family history of the condition are met. The CDC has designated genomics applications for these conditions as Tier 1, the highest tier on its evidence-based ranking system of genomic applications by their potential for a positive public health impact.

In a 2017 editorial published in American Family Physician, Vinay Prasad, MD, and Adam Obley, MD, of Oregon Health and Science University said that rigorous meta-analyses havent yet shown that genotype-guided dosing for warfarin, clopidogrel, or antidepressant selection is better than usual care. Prasad is a well-known critic of what he sees as the proliferation of medical treatments and therapies without good evidence behind them. We need to know on a broad scale that [these tests] improve outcomes for patients, and dont just reassure physicians theyre choosing a better drug, Obley tells Managed Care.

Prasad and Obley also argued in their editorial that without further proof of improved outcomes, routine genetic testing could just fuel more inappropriate care. Guidelines carve out clear boundaries for who should get tested because there are scenarios in which the risks and benefits of preventive measures arent known, they said, noting that the U.S. Preventive Services Task Force advises against genetic testing for BRCA mutations in women without a family history of BRCA-related cancers.

A small pilot study suggests that genetic testing in primary care may not lead to improved outcomes. In 2017, The Annals of Internal Medicine published the first randomized trial of whole-genome sequencing in primary care. Gene variants were found in 20% of the participants whose genomes were sequenced. But six months later none of them had improved outcomes.

The test produces lots of information, says Obley, who wasnt involved in the study. But its not clear that any patient was managed differently in a way that improved their health.

Without evidence supporting the clinical utility of routine pharmacogenomics or genetic testing, most payers are unwilling to cover them. Some exceptions exist, such as employers that offer routine genetic testing as an employee benefit. In a blog post published in 2018, Color Genomics touted Visa and the German software company SAP as customers. Medicare covers pharmacogenomic testing of two gene variants that predict warfarin responsiveness for beneficiaries enrolled in a randomized, controlled clinical study that meets certain standards.

The high cost of genetic testing has been cited as another reason insurance coverage is limited, but payers may not budge even as testing gets cheaper. The cost of doing the test itself has been declining quite rapidly, says Kathryn Phillips, a health economics professor at University of CaliforniaSan Francisco who researches personalized medicine access, quality, and reimbursement. She has disclosed in recent studies that she is a paid consultant for Illumina, a DNA sequencing company. But she says its hardand its going to take longerto figure out where to use genetics in primary care in healthy populations, and [for insurers] to pay for it.

The current state of evidence and bleak reimbursement prospects havent deterred early adopters from embracing precision medicine in primary care. For Megan Mahoney, MD, chief of general primary care at Stanford Medicine, precision medicine begins with going after data on key determinants of healthnot just genes, but also environmental factors, social determinants, and health behaviors.

In a yearlong pilot of 50 patientsmore than half of whom were at risk for cardiovascular conditionsStanford Medicine care teams created personalized care plans to prevent and manage chronic illness. The plans leveraged data from several sources, including genetic-risk assessments and genetic testing for the three CDC Tier 1 conditions and remote monitoring devices.

Before the pilot, which ended in 2018, Stanford did not offer routine genetic testing in primary care. So far, that hasnt changed. But Stanford is making the genetic-risk assessment tested in the pilot available to its primary care providers, hoping it can increase screening rates for the Tier 1 conditions, says Mahoney. Studies show that many primary care providers are uncomfortable evaluating and addressing genetic risk. Five patients in the pilot discovered through the genetic risk screening that theyre at high risk for breast cancer, demonstrating that this type of tool can help to identify previously unknown risks.

Post-pilot, Stanford is also offering patients with poorly controlled blood pressure connection to a Bluetooth-enabled blood pressure cuff and health coaching as part of a larger study. Genetic testing has dominated the discussion of precision medicine in primary care, but Stanfords experience shows that it isnt the only way to tailor preventive care to individual patients needs.

Even if clinical utility is ultimately shown, folding precision medicine into primary care will likely follow the path of many new developments in medicine: There will be some early adopters, but most practices will have a wait-and-see and depends-on-the-reimbursement attitude.

Educating doctors on how to interpret, use, and communicate genetic testing results to patients will be one of the biggest hurdles. Theyll be learning on the job, says Susanne Haga, associate professor of internal medicine at Duke Universitys medical school, who leads educational activities in genetics and genomics for the Duke Center for Applied Genomics. An obstacle course of other possible barriers awaits: the limited number of certified genetic counselors, concerns about privacy and genetic discrimination, and the potential for the lack of diversity in genomic data sets to exacerbate disparities in care.

Still, Haga sees the convergence of three factors that will force the health care systems hand and usher in precision medicine in primary care: patients increasing ability to influence decisions about their care, the declining cost of testing, and a critical mass of people, numbering in the millions, who will have had their DNA sequenced in genome programs such as Geisingers or several national genomics research initiatives.

Its coming, she says, one way or another.

Originally posted here:

Precision Medicine in Primary Care: Bespoke. Genetic and Genomic. And Maybe Not Ready. - Managed Care magazine

If you want to develop a new medicine, Boston is the place – The Boston Globe

If you were to go make a movie, youd go to Hollywood; if you want to develop a new medicine, Boston is the place, said Daphne Zohar, founder and CEO of PureTech Health, a Boston-based biotech company.

There are more than 700 biotech companies in the state, according to the Massachusetts Biotechnology Council, with roughly 500 residing in Boston and Cambridge. They employ some 75,000 people in Massachusetts, according to the Bureau of Labor Statistics, accounting for about $12 billion in wages 2018.

It all works because the nexus of top-tier research universities, world-class teaching hospitals, fledgling startups, and a few multinational pharma companies have created a critical mass straddling the Charles River.

Take, for example, Alnylam Pharmaceuticals. In 2002, the company began to explore a theory, co-discovered by a scientist at the University of Massachusetts Medical School, that tinkering with extracellular RNA communication might treat disease. It raised money from Boston VC Polaris Partners, leased a cramped space in Cambridge, and recruited a team from nearby biotech stalwarts Millennium Pharmaceuticals and Biogen. Fast-forward through a couple decades of scientific peaks and valleys, and Alnylam now has two FDA-approved medicines, a pipeline of nine more potential ones, and roughly 1,200 employees to bring the plan to fruition. All while staying in Massachusetts.

Such success stories were unimaginable about four decades prior, when Kendall Square was a stretch of warehouses and factories. Lita Nelsen, who enrolled at MIT in the 1960s, recalls that one could tell which way the wind was blowing by whether it smelled like the Lever Brothers soap plant or the Necco wafer factory.

All that would change in 1977, when Cambridge became the first city in the world to set rules around genetic engineering. The idea was to prevent an apocalyptic superbug from crawling out of some over-ambitious lab, but the effect was like an open-for-business sign to biotech entrepreneurs around the globe. Where other cities offered uncertainty, Cambridge had a workable blueprint.

Nelsen, who spent 30 years leading MITs office for out-licensing discoveries, was there to see Kendalls nascent biotech scene flourish. Biogen, Genzyme, and Repligen arrived in the early 1980s. Then came VCs from New York and California, lured by the promise of cutting-edge biology. By the late 1990s, Big Pharma took notice and began building research hubs alongside Cambridges many startups. In time, the biotech sector became a self-sufficient economic force.

I dont know what to say but that it happened, and then it built on itself, Nelsen said. Its a pretty complicated sauce. Youre never sure which ingredients are absolutely critical and which just help it along.

Massachusetts biotech companies are constantly getting launched, shuttered, or consumed, but the ecosystem persists because the people tend to stick around, said Samantha Truex, CEO of the recently formed Quench Bio. That makes it easy to recruit for the next startup idea, and it creates a multigenerational brain trust, available for free consulting in the line for coffee.

Its almost like an upward spiral, if you will, Truex said. Thats what has made it grow and flourish.

Massachusetts decades of success in biotech have inspired more than a few cities, states, and nations to try replicate that complicated sauce. It often creates a tricky game of chicken-or-egg. How do you attract entrepreneurial scientists if theres no anchor industry? And how do you rope in major drug companies if you dont have researchers to fill their pipelines?

There are way more failure stories than there are success stories, said Michael Ringel, a senior partner at Boston Consulting Group, who focuses on research and development. The failures tend to be around just throwing money at it and not realizing that theres a system that has to be put in place.

Damian Garde covers biotech for STAT. He can be reached at damian.garde@statnews.com. Follow him on Twitter @damiangarde.

Read the rest here:

If you want to develop a new medicine, Boston is the place - The Boston Globe

‘Lucky Dog’ Scout thanks UW School of Veterinary Medicine with WeatherTech Super Bowl Commercial – The Badger Herald

UW Madisons School of Veterinary Medicine had no idea saving one of their furry patients would land them on the biggest screen in America Scout, the Lucky Dog, and the School of Veterinary Medicine will be featured in a WeatherTech Super Bowl LIV commercial.

According to David Vail, UW Professor of Oncology and a member of Scouts treatment team, Scout first arrived at the UW School of Veterinary Medicine in 2019 following his unexpected collapse at his home in Illinois. Vail said Scout was diagnosed with a rare form of cancer with a tumor growing on his heart.

Vail said Scouts owner, David MacNeil, CEO and Founder of WeatherTech, was directed to experts at UW in the face of the cancers 1% survival rate at 12 months. Vail said the MacNeil family never gave up on Scout, and openly pursued the most aggressive form of treatment while maintaining the best quality of life possible for Scout .

[Scouts family] was very concerned and committed to Scout. They asked all the right questions, Vail said. The right patient and the right caregivers made him an excellent patient to treat.

WARF donates $15 million to expand UW School of Veterinary MedicineThe Wisconsin Alumni Research Foundation recently donated $15 million for expanding the current University of Wisconsin School of Veterinary Medicine. Read

Vail said Scout has a type of cancer in his blood vessels, making it difficult to treat, especially with the tumor on his heart. According to Vail, UW had the special radiation and imaging equipment needed to reach the heart tumor.

With this treatment, Vail said Scouts tumor shrank by about 90%. While Scout is still undergoing chemotherapy and immunotherapy to try to kill cancer cells in his body, Vail said Scouts been able to maintain his same quality of life.

Hes normal Scout. [The MacNeils] still fly him down to Florida where their second home is, Vail said. He swims in the ocean and runs on the beach.

WeatherTech completely funded the thirty-second commercial entitled Lucky Dog. The commercial will air most likely during the second quarter of the Super Bowl LIV game on Feb. 2, according to Milwaukee Journal Sentinel. It narrates Scouts journey with UW staff and encourages viewers to donate.

Mark Markel, Dean of the School of Veterinary Medicine, said the MacNeils ability to share Scouts story in a Super Bowl commercial is nothing short of extraordinary.

Scouts story is amazing. There is nothing like this, particularly in the context of a Super Bowl commercial, in any other higher educational institute, any university, and certainly not a school of medicine, Markel said. I think it is a testament to pet owners passion about their animals, that many consider them a member of the family.

Markel said all money received in relation to the commercial will go to cancer treatment or research. Markel said it will go towards funding treatment programs as well as state of the art equipment.

UW selected as national coordinating center for national cancer instituteThe University of Wisconsin has been selected as the national coordinating center for the National Cancer Institute Cancer Prevention Clinical Read

Vail said he believes the commercial will show people there is hope when dogs get cancer. With the Schools partnerships in comparative oncology for humans and animals, Vail said the money will help accelerate research in the one medicine idea the idea that all cancers in all species can be managed with the same approach to treat aggressive cancers for both people and pets.

Were really hopeful and very grateful to the MacNeils. They could have been content with just treating Scout, Vail said. Theyve decided they are not content with that and they want to take a more global approach to helping pet dogs with cancer.

Vail said Scout will spend all this week and next week undergoing radiation treatment for lung nodules, a result of the metastatic disease that comes with his cancer.

Vail said despite the low odds of completely eradicating the cancer, UW will keep fighting for Scout.

The likelihood of cure is not high, Vail said. But we are out to give him as much quality for as long as we can.

See the original post:

'Lucky Dog' Scout thanks UW School of Veterinary Medicine with WeatherTech Super Bowl Commercial - The Badger Herald

Immune responses to tuberculosis mapped across 3 species – Washington University School of Medicine in St. Louis

Visit the News Hub

Detailed genetic road map will guide research into TB treatments, vaccines

A new study led by Washington University School of Medicine in St. Louis lays out a genetic road map of immune responses to tuberculosis (TB) infection across three species. Pictured is a TB-infected human lung. TB is shown in green, and immune cells surrounding the TB bacteria are shown in red and white.

Tuberculosis (TB) is one of the worlds most vexing public health problems. About 1.5 million people died from this bacterial lung infection in 2018, and the World Health Organization (WHO) estimates that one-quarter of the worlds population some 2 billion people, mostly in developing countries are infected with the bacteria that causes TB.

For decades, scientists have been studying the deadly disease in mice and other animal models to develop drug therapies and vaccines to treat or prevent the infection. But findings in animals with TB dont always translate well to people with the disease, leaving scientists puzzled by the discrepancies.

Now, a new study led by Washington University School of Medicine in St. Louis offers a genetic road map detailing the similarities and differences in immune responses to TB across three species mice, macaques and humans. According to the researchers, the insight into the immune pathways that are activated in diverse models of TB infection will serve as a valuable tool for scientists studying and working to eradicate the disease.

The research, appearing Jan. 29 in the journal Science Translational Medicine, is a collaboration between Washington University; the Texas Biomedical Research Institute in San Antonio; and the University of Cape Town in South Africa.

For many years, scientists have been frustrated by the fact that animal models of TB especially the genetically identical mice so often studied dont really reflect what we see in people with TB infections, said co-senior author Shabaana A. Khader, PhD, a professor of molecular microbiology at Washington University. This study is important because now we show in great detail where these animal models overlap with humans with TB and where they dont.

Unlike many previous mouse studies, the new research involved genetically diverse mice that more closely recapitulate the wide range of TB infection severity in humans: Some infected individuals show no symptoms; others show intermediate degrees of severity; and still others develop extreme inflammation of the lungs.

With co-author Deepak Kaushal, PhD, at the Texas Biomedical Research Institute, the researchers compared the genetic and immune responses to TB infection in these diverse mice with the responses of TB-infected macaques in the Kaushal lab. And with co-author Thomas J. Scriba, PhD, of the University of Cape Town, the research team analyzed blood samples from adolescents in Western Cape, South Africa, who are enrolled in a clinical trial investigating TB infection. The samples from people allowed the researchers to analyze and compare data from the mice and macaques with a range of responses to TB infection in young people.

Past research from this long-running clinical trial identified a group of 16 genes whose activation patterns predicted the onset of TB disease more than a year before diagnosis. These genes called a human TB gene signature differed significantly in their activation patterns between young people who developed symptoms of TB and those who didnt.

In macaques, primates closely related to humans, scientists have long assumed that TB infection closely resembles such infection in people.

Our data demonstrate that 100% of the genes previously identified as a human TB gene signature overlap in macaques and people, said co-senior author Makedonka Mitreva, PhD, a professor of medicine and of genetics at Washington University and a researcher at the universitys McDonnell Genome Institute. Its important to have the definitive data showing it to be true.

There was significant overlap between humans and mice as well, according to the researchers, including co-first authors Mushtaq Ahmed, PhD, an assistant professor of molecular microbiology in Khaders lab; Shyamala Thirunavukkarasu, PhD, a staff scientist in Khaders lab; and Bruce A. Rosa, PhD, an assistant professor of medicine in Mitrevas lab. But they also identified genetic pathways that differed between mice and humans, providing detailed analysis of areas where TB in mice is unlikely to point to meaningful insight into human TB infection.

Until now, we have studied mouse models to understand TB disease progression, not knowing where the mouse disease translates to human disease and where it doesnt, Khader said. Now, we have shown that many areas do translate but that there are important aspects of TB infection that dont. If you are using mouse models to develop TB vaccines or other therapeutics that target areas that dont overlap, you likely wont succeed.

Added Mitreva, Our study will inform researchers when they may need to move to a different animal model to study their genetic or molecular pathways of interest.

The researchers studied in detail the genes that increase in expression in people who develop severe TB disease. Of 16 such genes identified in people, they were able to study 12 in mice. Four of the genes could not be studied because mice dont have equivalent versions of such genes or, when such genes were eliminated, the mouse embryos died during development.

The scientists found that the 12 genes fall into three categories: those that provide protection against TB infection; those that lead to greater susceptibility to TB infection; and those that had no effect either way. Such information will be useful in seeking future therapeutics that could, for example, boost effects of protective genes or shut down harmful ones.

According to Khader and Mitreva, their team plans to use the new knowledge to better understand TB infections that have become drug-resistant, a growing problem in places where the disease is endemic. In addition, they will harness the information to help understand why the TB vaccine often administered to high-risk groups of people works well in some individuals but not others.

With the studys raw data publicly available, Khader and Mitreva said they are hopeful it will serve as a valuable resource to TB research and immunology communities worldwide.

This work was supported by Washington University in St. Louis; the National Institutes of Health (NIH), grant numbers HL105427, AI111914-02, AI123780, AI134236-02, U19 AI91036 and U19AI106772; the Department of Molecular Microbiology at Washington University; and a Stephen I. Morse Fellowship; the Department of Medicine at the University of Rochester Medical Center.

Scriba is a co-inventor of a patent of the 16-gene signature for TB susceptibility from the Adolescent Cohort Study (ACS).

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

Go here to see the original:

Immune responses to tuberculosis mapped across 3 species - Washington University School of Medicine in St. Louis

Marketing, not medicine: Gwyneth Paltrows The Goop Lab whitewashes traditional health therapies for profit – The Conversation AU

In Gwyneth Paltrows new Netflix series, The Goop Lab, Paltrow explores a variety of wellness management approaches, from energy healing to psychedelic psychotherapy.

Goop has long been criticised for making unsubstantiated health claims and advancing pseudoscience, but the brand is incredibly popular. It was valued at over US$250 million (A$370 million) in 2019.

The alternative health industry is worth A$4.1 billion in Australia alone and projected to grow.

A key driver of the industry is increased health consciousness. With easier access to information, better health literacy, and open minds, consumers are increasingly seeking alternatives to managing their well-being.

Goop has capitalised on the rise in popularity of alternative health therapies treatments not commonly practised under mainstream Western medicine.

Health systems in countries such as Australia are based on Western medicine, eschewing traditional and indigenous practices. These Western systems operate on measurable and objective indicators of health and well-being, ignoring the fact subjective assessments such as job satisfaction and life contentment are just as important in evaluating quality of life.

This gap between objective measures and subjective assessments creates a gap in the marketplace brands can capitalise on not always for the benefit of the consumer.

The Goop Lab fails to engage with the cultural heritage of traditional health and well-being practices in any meaningful way, missing an important opportunity to forward the holistic health cause.

Read more: Gwyneth Paltrow's new Goop Lab is an infomercial for her pseudoscience business

The uncritical manner in which these therapies are presented, failure to attribute their traditional origins, absence of fact-checking, and lack of balanced representation of the arguments for and against these therapies only serve to set back the wellness cause.

Many of the historical and cultural origins of the therapies in The Goop Lab are not investigated, effectively whitewashing them.

The first episode, The Healing Trip, explores psychedelic psychotherapy, suggesting this is a new and novel approach to managing mental health.

In reality, psychedelics have been used in non-Western cultures for thousands of years, only recently enjoying a re-emergence in the Western world.

In the second episode, Cold Comfort, the Wim Hof Method (breathing techniques and cold therapy) is also marketed as a novel therapy.

The meditation component of Hofs method ignores its Hindu origins, documented in the Vedas from around 1500 BCE. The breathing component closely resembles pryma, a yogic breathing practice. The Hof dance looks a lot like tai chi, an ancient Chinese movement practice.

Whitewashing these alternative therapies represents a form of colonisation and commodification of non-Western practices that have existed for centuries.

The experts showcased are usually white and from Western cultures, rather than people of the cultures and ethnicities practising these therapies as part of their centuries-old traditions.

Rather than accessing these therapies from authentic, original sources, often the consumers only option is to turn to Western purveyors. Like Paltrow, these purveyors are business people capitalising on consumers desire and pursuit of wellness.

Paltrow describes Goop as a resource to help people optimise the self. But many of these therapies are economically inaccessible.

In The Health-Span Plan, Paltrow undergoes the five-day Fast Mimicking Diet by ProLon a diet designed to reap the health benefits of fasting while extremely restricting calories. The food for the treatment period costs US$249 (A$368) (but shipping is free!). The average Australian household spends just over A$250 on groceries weekly.

Paltrow also undergoes a vampire facial, where platelet-rich plasma extracted from your own blood is applied to your skin. This facial is available at one Sydney skin clinic for between A$550 and A$1,499.

These therapies commodify wellness and health as a luxury product, implying only the wealthy deserve to live well, and longer.

This sits in stark odds with the goals of the World Health Organisation, which views health as a fundamental human right without distinction of race, religion, political belief, economic, or social condition.

Companies like Goop have a responsibility to explain the science and the origins of the methods they explore.

Given their profit-driven motive, many absolve themselves of this responsibility with an easy disclaimer their content is intended to entertain and inform not provide medical advice. This pushes the burden of critically researching these therapies onto the consumer.

Governments should seek to fund public health systems, such as Medicare, to integrate traditional health practices from other cultures through consultation and working in collaboration with those cultures.

Read more: Traditional medicines must be integrated into health care for culturally diverse groups

Perhaps this will give everyone access to a wellness system to help us live well, longer. This way, citizens are less likely to be driven towards opportunists such as Goop seeking to capitalise on our fundamental human right to live well.

Follow this link:

Marketing, not medicine: Gwyneth Paltrows The Goop Lab whitewashes traditional health therapies for profit - The Conversation AU

Montefiore and Albert Einstein College of Medicine Secure $5.9 Million NCI Grant to Improve Cancer Care for Minority and Underserved Communities -…

BRONX, N.Y., Jan. 29, 2020 /PRNewswire/ -- Montefiore, the University Hospital ofAlbert Einstein College of Medicine, has received a $5.9 million grant from the National Cancer Institute (NCI) to build on its success recruiting minority and underserved patients into cancer clinical trials and delivering the highest quality cancer care. This new grant, part of the NCI Community Oncology Research Program (NCORP), is a continuation of funding first awarded in 2014.

"The most innovative cancer treatments are evaluated in clinical trialsoften years before they are broadly available in clinical practicesbut minorities are underrepresented in these trials," said Joseph A. Sparano, M.D., professor of medicine at Einstein, associate director for clinical research at the NCI-designated Albert Einstein Cancer Center, and associate chairman for clinical research, oncology at Montefiore. "Our continued funding from NCI is helping us correct this disparity. This is particularly relevant for the diverse population served by Montefiore and Einstein." Dr. Sparano is one of the principal investigators on the grant, along with Balazs Halmos, M.D, M.S., director, the Multidisciplinary Thoracic Oncology Program at Montefiore and professor, clinical medicine at Einstein, and Bruce D. Rapkin, Ph.D., professor of epidemiology & population health at Einstein and Montefiore.

One of Montefiore and Einstein's most notable achievements supported by NCORP funding was the landmark TAILORxclinical trial. The study, which found that 70% of women with the most common type of breast cancer could safely skip chemotherapy, immediately changed clinical guidelines for women around the world. Dr. Sparano, who also served as chair of the TAILORx study, reported comparable findings for women of African-American and Hispanic descent within the overall study population.

In addition, Haejin In, M.D., M.B.A., M.P.H., assistant professor of surgery and of epidemiology and population health at Einstein, and a cancer surgeon at Montefiore, is co-leading an effort to develop a cost-effective model to detect stomach cancer earlier, building on her prior research demonstrating most people with stomach cancer are diagnosed in hospital emergency departments when the disease is already too advanced to treat effectively.

Together, Montefiore and Einstein are one of only 14 NCORP Minority/Underserved Clinical Sites, which must have a patient population of at least 30% racial/ethnic minorities or rural residents. Approximately 80% of Montefiore and Einstein clinical trial participants are minorities compared to 8% nationwide.

NCORP trials now also include tissue collection, so researchers can study biological mechanisms, including those that prevent treatments from being effective across different racial and ethnic groups. As Dr. Halmos explains: "Having our patients, who are predominantly minorities, participate in cutting-edge clinical trials helps researchers strengthen the scientific evidence for various cancer therapies. We expect this to not only benefit our patients but improve care at hospitals and clinics worldwide."

The goals of the Montefiore and Einstein NCORP grant are to continue recruiting patients to the clinical trial network, maintain leadership at national scientific organizations like ECOG-ACRIN that design and conduct clinical cancer research, mentor young investigators and contribute to knowledge that will address cancer health disparities.

In addition to clinical trials focused on cancer diagnosis and treatment, Dr. Rapkin is leading the charge in studying where, when and how care is delivered, otherwise known as cancer care delivery research (CCDR). Montefiore and Einstein are part of a NCORP network of more than 900 hospitals, cancer centers and oncology clinics across 39 states eligible to participate in CCDR studies.

"Cancer disparities don't exist in a vacuum," said Dr. Rapkin. "They span genetic, social, economic and cultural factors. By participating in NCORP, we have access to more information about what might be preventing people from getting the best care possible and a real opportunity to improve cancer prevention, treatment and survivorship care for all."

Albert Einstein Cancer Center, a leader in basic and clinical cancer research and population-based studies, has been an NCI-designated center for almost 50 years.

About Montefiore Health SystemMontefiore Health System is one of New York's premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 11 hospitals, including the Children's Hospital at Montefiore, Burke Rehabilitation Hospital and more than 200 outpatient ambulatory care sites. The advanced clinical and translational research at its medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit http://www.montefiore.org. Followus onTwitterand view us onFacebookandYouTube.

About Albert Einstein College of MedicineAlbert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. During the 2019-20 academic year, Einstein is home to 724 M.D. students, 158 Ph.D. students, 106 students in the combined M.D./Ph.D. program, and 265 postdoctoral research fellows. The College of Medicine has more than 1,800 full-time faculty members located on the main campus and at its clinical affiliates. In 2019, Einstein received more than $178 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States through Montefiore and an affiliation network involving hospitals and medical centers in the Bronx, Brooklyn and on Long Island. For more information, please visit http://www.einstein.yu.edu, read our blog, followus on Twitter, like us on Facebook, and view us on YouTube.

Read this article:

Montefiore and Albert Einstein College of Medicine Secure $5.9 Million NCI Grant to Improve Cancer Care for Minority and Underserved Communities -...

Dr. Dori Borjesson named dean of the WSU College of Veterinary Medicine – WSU News

Dr. Dori Borjesson

PULLMAN, Wash. Dr. Dori Borjesson, chair of the Department of Pathology, Microbiology and Immunology at the University of California Davis School of Veterinary Medicine, has been selected as the new dean of the WSU College of Veterinary Medicine.

Borjesson was chosen following a nationwide search to replace Dr. Bryan Slinker, who had announced plans to retire before being tapped to serve as interim provost. She will assume her new responsibilities leading WSUs cutting-edge veterinary, biosciences and global health departments on July 20.

The strength of Washington State Universitys research and its potential to impact communities locally and across the globe impressed me during the interview process, as did its dynamic clinical programs and the Washington-Idaho-Montana-Utah Regional Program in Veterinary Medicine, Borjesson said.

Im looking forward to building on Dr. Slinkers tremendous tenure of leadership, she continued. The enthusiasm for WSU among the community is impressive, and I look forward to building on that momentum.

In addition to her role as a department chair and full professor at UC Davis, Borjesson works as a clinical pathologist and is actively engaged in clinical service and laboratory test development. She served as the inaugural director of the Veterinary Institute for Regenerative Cures from 2015 to 2019 and continues to direct the Clinical Regenerative Medicine Laboratory.

Dr. Borjesson brings an important combination of strengths and experience to make her the right leader for the college, Slinker said. Shes a long-serving, highly regarded, and very effective academic leader, and an excellent clinician/scientist, at an aspirational peer institution. This background, combined with her intellectual rigor, openness, and compassion make her a great fit to lead the college in its next phase of growth and development as one of the nations top veterinary colleges.

Borjesson said shes thrilled to meet with WSU students, staff and faculty, as well as meeting with college and university stakeholders in the near future.

Being from the Pacific Northwest, this feels like a homecoming, said Borjesson, who was raised in Portland, Ore. Increasing engagement and outreach across the state is a top priority for me upon taking up this new role. In addition to engagement and strategic planning, Im also eager to face some of the critical issues facing members of the veterinary profession, including student debt and enhancing the well-being of our faculty, students and staff.

Among her more notable research contributions is using large animal models of disease to study cell therapy for inflammatory diseases.

Borjesson holds two patents in the area of mesenchymal stem cells and immunomodulation and has contributed to more than 100 peer-reviewed publications, and in 2014 received the Zoetis Research Excellence Award. Alongside her own work, she has mentored more than three dozen veterinary residents and graduate students.

She and her colleague Dr. Aijun Wangs work with stem cells was highlighted in an extensive piece in the Los Angeles Times in 2018 about UC Davis Veterinary Medical Teaching Hospital.

Borjesson received her undergraduate education from the Colorado College in 1988, her Master in Preventive Veterinary Medicine and Doctor of Veterinary Medicine degrees from UC Davis in 1995. She completed a residency at UC Davis in clinical pathology in 1999, followed by her PhD in comparative pathology at the Center for Comparative Medicine at UC Davis in 2002.

After completing her PhD, Borjesson accepted an assistant professorship at the University of Minnesota, where she worked for four years before returning to UC Davis as an associate professor in 2006. She became a full professor in 2012. She has led the Integrative Pathobiology Graduate Group at UC Davis and is actively engaged in veterinary and graduate student curriculum development, teaching and mentoring.

Established in 1899, the WSU College of Veterinary Medicine is proud of its distinguished past as one of the oldest veterinary colleges in the United States. It is equally proud of its contemporary leadership nationally in offering programs for student wellness, its Teaching Academy, which leads its commitment to advancing the state of the art in both health professions and STEM education, and its research and graduate education programs. The breadth of research to discover foundational knowledge and to conduct research targeted to improve animal and human health both domestically and around the world places it in the top 10% of veterinary colleges in receipt of competitive federal research funding.

Phil Weiler, vicepresident for marketing and communications, 5093351221, phil.weiler@wsu.edu

View original post here:

Dr. Dori Borjesson named dean of the WSU College of Veterinary Medicine - WSU News

It Doesn’t Taste Good, but the Market Finally Swallows its Medicine – TheStreet

On any day when the indexes are down more than 1.5% or more, bulls are going to suffer some losses. While it may not feel very good, what happened Monday is exactly what this market needed. Technically conditions have become quite stretched and efforts at any sort of corrective action have been consistently rebuffed.

Over and over again, we have heard that the market can't correct due to the flood of liquidity. That has rendered valuation arguments meaningless, but what no one saw coming was the spread of a deadly virus that has effectively shut down the economy in China.

The confluence of extended market conditions and a negative news catalyst is almost perfect and now the question is how deep the correction will go before some solid support is found.

There is still not enough clarity about this virus to enable aggressive buyers to jump in. While the number of deaths and other statistics seems fairly small, there still isn't any idea how much further this will spread. There will be a widespread economic contraction in Asia, even if containment is achieved very quickly, but that will take a couple of weeks at an absolute minimum. The likelihood of more negative headlines is quite high.

While breadth was quite poorMonday with around 1,675 gainers to 5,850 decliners, one interesting aspect of the action is that the small-cap index iShares Russell 2000 Index (IWM) lost just 1.13% compared with over a 2% loss in the Nasdaq 100 (QQQ) . The big caps there were much more extended that the small caps corrected more which is exactly what we would hope to see.

The good news about the action of this sort is that it will eventually lead to some good stock picking. The bulk of small caps report in a week or two and there should be some interesting setups.

Don't forget that earnings reports hit with Apple (AAPL) being the big news on Tuesday night.

Overall this market is acting like a very normal market and it is refreshing to see. It may not cause much celebration, but this is what a healthy market does on a periodic basis and it will lead us to a new crop of opportunities.

Have a great evening. I'll see you tomorrow.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Original post:

It Doesn't Taste Good, but the Market Finally Swallows its Medicine - TheStreet

MLBTR Poll: How Good Are The Reds? – The Union Journal

The Reds went into the offseason on the heels of their 6th straight below-.500 proving, however head of state of baseball procedures Dick Williams made it recognized at the end of the project that a 7th successive substandard initiative would not serve. The groups objective when the wintertime started was to construct its initial playoff-level lineup given that 2013, and also with a lot of its offseason hefty training most likely done now, theres a situation Cincinnati has actually done simply that.

As we kept in mind formerly, the Reds have actually been just one of the highest-spending groups in the National League in totally free company. They have actually included 2 $64 MM gamers infielder Mike Moustakas and also freshly authorized outfielder Nick Castellanos in addition to $21 MM outfielder Shogo Akiyama (their first-ever Japanese gamer) and also $15 MM left-hander Wade Miley by means of the free market.

Now, the Reds placement gamer actors a team that completed last period 21 st in BATTLE and also 25 th in runs unexpectedly looks appealing with Castellanos, Akiyama and also some mix of Jesse Winker, Aristides Aquino and also Nick Senzel in the outfield, Joey Votto initially base, Moustakas at 2nd and also Eugenio Suarez at 3rd. But there are inquiries in the team, consisting of the wellness of the 49- crowning achievement guy Suarez that might miss out on the start of the period after going through ideal shoulder surgical procedure and also the stamina of their catcher and also shortstop placements. Both areas looked ripe for upgrades when the offseason started, however the Reds have actually thus far stuck to Tucker Barnhart and also Freddy Galvis, specifically, in spite of their rate of interest in landing a a lot more powerful choice at brief. Moreover, theres the opportunity of a Senzel profession, which might supply an useful return for among the Reds vulnerable points, however Williams does not seem like somebody that prepares to deal the treasured 24- year-old.

Meanwhile, there does not seem a great deal to bother with in the Reds beginning team. Luis Castillo, Sonny Gray, Trevor Bauer, Anthony DeSclafani and also Miley make up an excellent one to 5 theoretically, though Bauer did have greater than a little of problem protecting against pursue the Reds got him from the Indians lastJuly The bullpen, although mostly unblemished this offseason, additionally flaunts its share of stone-cold locks. Raisel Iglesias, Michael Lorenzen, Robert Stephenson and also Amir Garrett are all returning after uploading decent or much better numbers in 2019.

While it behaves for the Reds that they have actually improved their lineup given that last periods 75- win initiative, its additionally a benefit that their department has actually relatively taken go back. The Cardinals won the NL Central in 2019, however they have not done anything all that significant given that, and also they simply shed theirNo 1 freelance, outfielder Marcell Ozuna, to theBraves The Brewers fresh off their 2nd straight playoff period have actually seen many adjustments (good and also negative) to their lineup, consisting of the losses of Moustakas and also an also much better freelance in catcher Yasmani Grandal The Cubs have actually been silent after a disappointing coating to last period, and also its still not out of the world of opportunity theyll trade Kris Bryant or one more vital participant of their lineup prior to the brand-new project rolls around. And after that theres the Pirates, that figure to be amongst the most awful groups in the video game this year.

Between the renovations they have actually made and also the activities (or do not have thereof) of their local enemies, this might be the moment for the Reds to go back to importance in the NL. The method their lineup looks currently, do you assume they can doing so?

(Poll web link for application individuals)

View original post here:

MLBTR Poll: How Good Are The Reds? - The Union Journal

Grimmfest 2020: Screen Classic Horror Movies as Part of Their Horror Legends Season – ScreenAnarchy

Our friends at Grimmfest have announced a very cool series of All-Dayers, single days devoted to horror cinema pioneers and trailblazers.

In the back half of this new year the festival will pay tribute to Tobe Hooper, David Cronenberg, John Carpenter and Wes Craven. Each All-Dayers will include choice selections from each filmmakers filmography.

And right now they are hosting a social media competition to win an amazing Grimmfest horror movie goodie bag and 2 x passes for our first event, TOBE HOOPER ALL-DAYER.

See all the films from each day and find the link to the Tobe Hooper contest below.

In 2020, Grimmfest and Horror Channel pays tribute to four Legends of Horror, in the suitably elegant, art-deco surroundings of Stockport Plaza. Experience classics of the genre in suitably grand, elegant style, in the most beautiful Picture Palace in the region.

Join us through 2020 for some classic horror movies from four of the truly great directors, Tobe Hooper (9/2/20), David Cronenberg (8/3/20), John Carpenter (9/5/20) and Wes Craven (5/7/20). 16 movies in total over 4 special day events.

All events start at 1.00pm prompt!

TOBE HOOPER SUNDAY 9/2/20

No matter where youre going its the wrong place. Tobe Hooper.

TEXAS CHAINSAW MASSACRE (18 Cert)

Described as an exercise in the pornography of terror by James Ferman, former head of the BBFC, it was recently added to the permanent collection of the Museum of Modern Art in 1981.

POLTERGEIST (114 mins) (15 Cert)

Theyre heeeeerrrre! Spielberg tries his hand at horror, but is smart enough to enlist Hooper to direct.

TEXAS CHAINSAW MASSACRE 2 (18 Cert)

Leatherface is back. And this time hes got Dennis Hopper to answer to.

SALEMS LOT (180 mins) (15 Cert)

Nosferatu in Small Town America, in Hoopers classic adaptation of Stephen Kings novel.

DAVID CRONENBERG - SUNDAY 8/3/20

Everybodys a mad scientist, and life is their lab. Were all trying to experiment to find a way to live, to solve problems, to fend off madness and chaos. David Cronenberg.

RABID (15 Cert)

In the wake of the Soska Twins recent remake, a chance to revisit the stark, bleak original; the film in which Marilyn Chambers truly is insatiable.

VIDEODROME (18 Cert)

Long live the new flesh! Remember the whole video nasties hysteria of the 1980s? Fear of what exposure to such things might be doing to the young? It could have been a lot worse.

THE FLY (18 Cert)

There was an old lady who swallowed a fly. I dont know why. Perhaps shell die One of the genres greatest ever love stories. Yes, seriously.

CRASH (18 Cert)

Cronenbergs cinematic reimagining of J.G Ballards novel was described as beyond the bounds of depravity by critic Alexander Walker. The perfect combination of filmmaker and source material, in other words.

JOHN CARPENTER - SATURDAY 9/5/20

In France, Im an auteur, in Germany a filmmaker, in England a genre film director, in the USA a bum! John Carpenter.

PRINCE OF DARKNESS (15 Cert)

Carpenters homage to Nigel Kneales Quatermass series. With added satanism. And Alice Cooper.

BIG TROUBLE IN LITTLE CHINA (15 Cert)

Every 70s martial arts movie you ever loved put into a blender, and then thrown at Kurt Russell. Who comes out fighting.

THEY LIVE (18 Cert)

Rowdy Roddy Piper is all out of chewing gum. Those alien invaders had better watch out. The perfect combination of poltical satire and all-in wrestling.

IN THE MOUTH OF MADNESS (15 Cert)

Gods not supposed to be a hack horror writer. But lets face it, that would actually explain a lot

WES CRAVEN - SUNDAY 5/7/20

Wes Craven reinvented horror at least four times. Most directors dont even manage it once. Kim Newman.

THE HILLS HAVE EYES (18 Cert)

Family values in conflict; a stark and brutal confrontation between civilisation and savagery in which the lines between the two become increasingly blurred.

SCREAM (18 Cert)

Visit link:

Grimmfest 2020: Screen Classic Horror Movies as Part of Their Horror Legends Season - ScreenAnarchy

A Modern Witch’s Guide to Paris: Where to Find the Occult and Esoteric – Frenchly

Despite the fact that Halloween is long gone, witch season never ends, a subject The New York Times recently delved into in an article, When Did Everybody Become A Witch? But Paris has a long history of fascination with the occult, particularly in its Belle poque heyday, and there are still a few places in the city rife with witchiness and wonder. Here are some of our favorites.

Advertisement

La Maison de la Radiesthsie, or House of Divination, is the oldest (and one of the last) esoteric stores in Paris. You can buy wands, pendulums, and divination rods, starting in a reasonable 10 range, and working up into the designer realm. 22 Rue Godot de Mauroy, 75009

And of course, theres nothing better, when youre in the mood, than a good ol fashioned haunted house. Le Manoir de Paris has been putting up its trademark Legends of Paris show for almost a decade, featuring all kinds of creepy and gruesome characters from Pariss history. Keep an eye out for special events like their annual Halloween show, and a performance called Dark Night that occurs every Friday the 13th. 18 Rue de Paradis, 75010

A bookstore that refers to itself as a Librairie sotrique, Arc en Ciel is a place for anyone who needs an non-ironic crystal ball or tarot cards. Among the books, find anything on topics ranging from reiki and aromatherapy to yoga and plant care. They host workshops, seminars, and meet-ups for those inclined towards the spiritual and the occult. 3 Rue Jean-Mac, 75011

Brsilophile in Passage Jouffroy is a great place to find any kind of rare or exotic crystals you need to perform whatever witchcraft youve learned from your reading at Arc en Ciel. Loose beads, precious stones, and even an esoteric crystal collection should cover anything youre looking for, from rose quartz to tourmaline. 40 Passage Jouffroy, 75009

You might recognize the Church of Saint-Merri, because it sits right beside the Stravinsky fountain, and one of the more famous murals of the Marais. But this medieval church got some surprising sprucing up in the mid-1800s, when a Baphomet was carved above the entranceway. The demonic figure is heavily used in Satanism, and among the Knights Templar, and its accompaniment by a prominently-placed stained glass depiction of a pentagram makes this one curious church. 76 Rue de la Verrerie, 75004

For one-of-a-kind trinkets, statement pieces, and magic charms, try the office of Xenia Rybina, a Parisian witch, illustrator, and fashion designer come to France by way of Russia. Everything is witchcraft around [us] Rybina says in an interview with Messy Nessy Chic at her home/workshop in Paris, which she lovingly refers to as her coven. And with a snake named Seraphim and a cat named Lucifer, its easy to believe that everything is witchcraft around Xenia Rybina, whose berets embroidered with eyes and tiny, exquisite spider dolls have an effect at once whimsical and uncanny. Xenias work will soon be available in her e-shop. In the meantime, shes selling items via Instagram (DM her for prices).

Hidden in a backstreet of Montmartre, in front of the Hotel Particulier Montmartre (one of the most exclusive boutique hotels in the city), is a lumpy hunk of rock called the Rocher de la Sorcire, or Witchs Rock. The rock, and the entire passage, was named for the old woman who lived in the house, called la soucire, or the dowser. (In case youre wondering, a dowser is someone who uses a divination rod.) No one quite knows where it came from, but some believe it might still have some powerful magic inside. Passage de la Sorcire, 75018

Though the interior has been refurbished into a modern restaurant, the exterior of the Auberge Nicolas Flamel is the same simple stone facade that was built to be an inn in 1407 by Nicolas Flamel and his wife. This makes it the oldest stone building in Paris, a pretty impressive feat in such a well-preserved city. If the name Nicolas Flamel rings a bell, you might recognize it from Harry Potter and the Sorcerers Stone. Both in the book and in real life, Flamel, probably the most recognizable name in the history of alchemy, was famous for allegedly creating a Philosphers stone, which had powers such as transforming ordinary metals into gold. 51 Rue de Montmorency, 75003

Featured image: Stock Photosfrom Vera Petruk / Shutterstock

Read more here:

A Modern Witch's Guide to Paris: Where to Find the Occult and Esoteric - Frenchly

Lord Jeffery Amherst, the town namesake who attempted a Native American genocide – Buffalo News

Sue Miller Youngs 1965 definitive history of the Town of Amherst says that the town was indirectly named for British North American Commander-in-Chief Lord Jeffery Amherst. Indirectly, because when the town was incorporated in 1818, she surmises the early town fathers were likely thinking of Amherst, Mass., which was named after the British soldier and politician.

For many years, Amherst's hospitality was served up at a motor lodge named the Lord Amherst Hotel at Main and Kensington.

Its not likely that those town fathers knew of the generals implicit statements in favor of giving smallpox-infected blankets to enemy indigenous people, and thereby engaging in genocidal germ warfare.

In her 306-page A History of the Town of Amherst, Young writes that Lord Amherst was reputed to be grave, formal, and cold, and continues, It is ironic that his name became the name of a town that is pleased to be characterized by friendliness, suburban informality, and warm hospitality.

But grave and cold is barely the tip of the iceberg.

You can read the letters written in then-General Amhersts own hand during the French and Indian War, as collected by UMASS Amherst Professor Dr. Peter dErrico on his website.

In one letter, Amherst writes, Could it not be contrived to send the Small Pox among those disaffected tribes of Indians? We must on this occasion use every stratagem in our power to reduce them.

In approving of one colonels plan to leave disease-laden blankets for the Native Americans to use, Amherst writes, "You will do well to try to inoculate the Indians by means of blankets." In the same letter, he also suggests allowing dogs to chase down and kill them, ordering his men "to try Every other method that can serve to Extirpate this Execrable Race."

Amhersts motives were to kill as many indigenous people by whatever means necessary; to put a most Effectual Stop to their very Being, he wrote, the underlining to their very being.

In other Amherst communities around North America, there have been movements to remove Lord Amhersts name that have been met with varying degrees of success.

One man who worked in Amherst, Mass., says his petition for a name change didnt get very far.

"The town did respond and they said they are not willing to change the name of the town point-blank because of the cost of changing everything," William Bowen told Masslive.com. "I didn't get much response back from the Legislature."

In 2017, Amherst, Nova Scotias town council voted to keep its name but leave the door open for future discussion. That was also the thought of the mayor of Amherstburg, Ont., near Windsor.

There have been changes as well. Amherst College changed their sports nickname from the Lord Jeffs to the Mammoths. In Montreal, the mayor said Amherst was a stain on the citys history as he ordered the 2017 change of Rue Amherst to a name with roots in indigenous culture.

Continued here:

Lord Jeffery Amherst, the town namesake who attempted a Native American genocide - Buffalo News

DC Hero’s Most Disgusting Power Was Popular With The President – Screen Rant

DC Comics Legion of Substitute Heroes is a fan-favorite super team, being a spin-off of the better-known Legion of Super-Heroes, DCs premiere superhero team of the 31st century. The Substitutes consist of would-be heroes that didnt make the cut in the main Legions superhero auditions but still wanted to help others. As such, they formed their own team, vowing to perform substitute superhero services when the main Legion couldnt spare the time.

The Legion of Substitute Heroes spoke to many fans who felt slighted by the mainstream cool kids like the Legion of Super-Heroes. The team also inspired some endearing characters with offbeat powers but few had a weirder name or power set than Drura Sehpt, aka Infectious Lass. Known for having the dubious power to make people sick, Infectious Lass seemed doomed to be a pariah, even among other superhero rejects.

Related: Which Marvel Superhero Has The Most Valuable Blood?

Yet, surprisingly, the girl who had literally every illness in the universe proved quite popular with men. In one continuity, she even went on to marry Jacques Foccart, the second Invisible Kid, and the President of Earth. Theyre probably one of the more unusual couples in the DC Universe, but perhaps a closer look at Infectious Lass can reveal why guys want to reach out to the girl with all the diseases.

Infectious Lass first appeared in Superboy Vol. 1 #201. An alien from the planet Somahtur, Infectious Lass people have bodies that house colonies of bacteria that they themselves have become immune to. Believing she could use this quality to become a superhero, Dura designed a costume (complete with a mask and cape that looks like dripping mucus) and auditioned for the Legion of Super-Heroes.

Although Infectious Lass powers could potentially be a huge asset (just imagine how ineffective a team of supervillains could be if they all suddenly came down with stomach flu), she often had a hard time aiming her diseases or turning them off. As a result, she often accidentally made her teammates sick as shown when she made Legionnaire Star Boy horribly ill during her audition. To top it off, some of Infectious Lass otherworldly illnesses were just plain weird and did bizarre things to other people like the time she accidentally hit Color Kid with a gender-switching virus.

Despite this, Infectious Lass soon gained membership in The Legion of Substitute Heroes who thought she deserved a chance to prove herself. Her friendly, somewhat nerdy personality made her an endearing recruit, but the nature of her powers did make her very insecure in some stories. In one hilarious story, she attempts to seduce Ambush Bug with her feminine wiles but proves completely inept, even telling him how she makes people sick while trying to make small talk. In another story, she bemoans the fact that Ill never know the tender touch of a man, prompting one of her teammates to suggest she change her name.

As time went on, however, Infectious Lass grew more attractive in both looks and personality. Perhaps artists and writers found the dichotomy of a kind-hearted woman in a lethal body weirdly titillating, but Infectious Lass began to be drawn in a more seductive matter. Where her earlier appearances emphasized her gross, phlegm-like costume, during the 1990s, Drura was frequently depicted posing in bedsheets and lingerie. Moreover, she was clearly sleeping with Legion of Super-Heroes member Invisible Kid indicating that she had finally achieved some control over her powers (in the past her merest touch usually sent men into convulsions).

Related:Batmans Son is Joining DC's Legion of Super-Heroes, Too

Infectious Lass also finally gained membership in the official Legion of Superheroes. While this was initially seen as a way of simply filling the ranks after the main members all left the team, Drura still managed to serve with distinction infecting only those she chose to. Moreover, she ended up marrying the Invisible Kid and when he became Earth President wound up becoming First Lady and living in the London Presidential Palace. Drura even became one of her husbands advisors, showing how she had grown in confidence since her early appearances.

Unfortunately, during the Zero Hour storyline, Infectious Lass was wiped from the timeline. She later showed up in a rebooted universe, once again trying out for the Legion of Superheroes. It wasnt a complete backslide, however, as Drura was shown to still have better control over her germ warfare abilities. In Legion #37, Infectious Lass is actually accepted into Legion Academy and is even considered one of their most promising cadets. Once again clad in her mask and costume, Infectious Lass is nonetheless still showcased as an attractive young woman more exotic alien than a gross sick girl.

And while Druras relationship with the Earth President appears to have been retconned out of existence, her popularity with men has apparently not waned. In Tales of the Unexpected #4, another rebooted version of Infectious Lass showed up in the past fighting a group of powerful overlords known as the Architects. Again wearing her classic mucus-like costume, Infectious Lass retained her cheerful attitude and managed to attract the swashbuckling pirate Captain Fear who confessed Drura left him lovesick.

For a character initially designed as a joke for the Legion of Super-Heroes, Infectious Lass has acquired a remarkably devoted following. Although the Legion has probably gone through more reboots than any other superhero team in the DC Multiverse, making her current status (or even existence) questionable, theres an excellent chance this fan-favorite character will show up again complete with some new admirers!

Next: How Morbius Saved Spider-Man With His Poisoned Blood

The Final Death of DEADPOOL Revealed By Marvel Comics

Michael Jung is a mild-mannered freelance writer-for-hire, actor, and professional storyteller with a keen interest in pop culture, education, nonprofit organizations, and unusual side hustles. His work has been featured in Screen Rant, ASU Now, Sell Books Fast, Study.com, and Free Arts among others. A graduate of Arizona State University with a PhD in 20th Century American Literature, Michael has written novels, short stories, stage plays, screenplays, and how-to manuals.

Michaels background in storytelling draws him to find the most fascinating aspects of any topic and transform them into a narrative that informs and entertains the reader. Thanks to a life spent immersed in comic books and movies, Michael is always ready to infuse his articles with offbeat bits of trivia for an extra layer of fun. In his spare time, you can find him entertaining kids as Spider-Man or Darth Vader at birthday parties or scaring the heck out of them at haunted houses.

Visit Michael Jungs website for information on how to hire him, follow him on Twitter Michael50834213, or contact him directly: michael(at)michaeljungwriter(dot)com.

Visit link:

DC Hero's Most Disgusting Power Was Popular With The President - Screen Rant

As China death toll rises, do we need a vaccine for the virus of State secrecy – The Conservative Woman

THE death toll from the coronavirus continues to rise in China, and with it the conspiracy theories. Amidst all the horse-pucky in the latter, you will often find a seed or two of truth.

For example, we now know that Wuhan, the city where the outbreak started, is also the location of Chinas only Level 4 (the highest level) biological research facility, or the only one were allowed to know about.

Someone connected this with the escorted departure of some Chinese scientists from a similar laboratory in Winnipeg, Canada. No-no-no, said the Canadian Broadcasting Corporation: Online chatter disinformation (watch for that word with Google Alerts, theres an organised official counter-attack against social media infospread) before reminding us of one of its earlier stories that revealed the National Microbiology Lab had sent live ebola and henipah viruses to Beijing on an Air Canada flight last March. Good job planes never crash.

The Chinese probably didnt need shipments of coronavirus, though. After all, their SARS epidemic 18 years ago was another version of the same class of virus. The earlier one was traced back to cave bats in Yunnan; the latest has also been blamed on bats and a Chinese vlogger has had to apologisefor commending them as a delicacy (like almost everything else: If its back is towards Heaven you can eat it, is the old Cantonese saying) or is that explanation itself official disinformation?

Could it possibly have been anAndromeda Strain-typeaccidental lab release? The 1975 (effective date) international Biological Weapons Conventionprohibits the military development, production etc, of germs and viruses, and China signed up in 1984. Yet, given the fallen state of mankind and especially governments, I shouldnt be surprised if it hasnt continued undercover there, as this writer claims.

Asked where the UK does its bio and chemical research, most of us could only name Porton Down (I remember the Aldermaston marches, but when did the public march against germ warfare?)

However, we have another facility in Hertfordshire, three in Surrey and three more in Greater London. I hope its all white-hat stuff, though I can imagine Whitehall arguments for developing nasties in order to find defences against them if the other side tries to use them.

There are two in France and another French-supported one in Gabon, on the coast of West Africa. They do like to do things their own way, do the French; unlike us, they dont need US authorisation for their nukes, either. A reason I pick on our Continental cousins here is a story that caught my eye in 2016, about the opening of a Level 3 (allegedly) bio-safety laboratory in French Polynesia. Funnily enough, thatTahiti Newsarticlehas since disappeared.

The Institut Louis Malard (ILM) opened the lab, not on the main island of Tahiti or in Papeete, but on a tiny two-square-mile atoll called Tetiaroa. Supposedly it is for research into mosquito-borne diseases and having it locally would save processing time, according to France.tv. Google flagged up an article on the ILM sitewith a snippet under the link Lutte contre les moustiques. Une exprimentation innovante Tetiaroa that now I cant find there.

Colour me sceptical, but we have every reason to distrust our rulers and their massive military establishments. Humans arent grown-up enough to play with such toys; the trouble is getting them back into the box.

Its easier to keep us in the dark, I guess. New definition of a British D-notice: Dis information must not be released to da public.

- Advertisement -

Read the original here:

As China death toll rises, do we need a vaccine for the virus of State secrecy - The Conservative Woman

An Indian Doctor Claims to Have Found a Herbal Cure for Coronavirus – VICE

The scariest part about the coronavirus that has been taking over global headlines is that doctors have yet to find any cure, even as scientists make a preventative vaccine that will reportedly only be available a year from now.

The virus which was first reported in Chinas Wuhan province in December and has more than 7,000 confirmed cases and a death toll of more than 170 has now spread to at least 15 countries, with Indias first case just being confirmed in Kerala today. While Indias alternative medicine ministryThe Ministry of Ayurveda, Yoga & Naturopathy, Unani, Siddha, Sowa Rigpa and Homoeopathy (AYUSH)has recommended herbal remedies and homeopathy to prevent the symptoms of coronavirus, one doctor from the state of Tamil Nadu claims to have found a cure for the virus.

Dr Thanikasalam Veni from Chennai, who has 25 years of experience in Ayurvedic medicine, says he has come up with a herbal cure for coronavirus that he believes could actually be effective. "We have formulated medicine from an extract of herbs. It is very effective to cure any type of viral fever," he told ANI. Coronavirus has no medicine. In China's Wuhan where Coronavirus has claimed over 50 lives, experts have no idea how to cure the disease. Our herbal extract medicine is used to treat dengue, multi-organ fever and acute liver fever." He also addressed the World Health Organisation (WHO) while speaking to the media and said that the medicine would work well to treat organ failure in coronavirus patients. "When we treated the dengue virus with our medicine, many patients with reduced platelets count, acute liver failure, immunity deficiency and low white blood cell (WBC) were cured within 24-40 hours," said Veni, who even offered to travel to Wuhan and test out his cure.

This comes just as Indias AYUSH ministry is facing flak online for saying Ayurveda could prevent coronavirus and releasing a list of herbal remedies that they believe can help provide relief to patients. Many are calling the claim misinformation and ill-timed. With no scientific backing to Dr Venis alleged cure either, the advisory can be seriously misleading for those experiencing coronavirus symptoms.

Follow Shamani Joshi on Instagram.

Original post:

An Indian Doctor Claims to Have Found a Herbal Cure for Coronavirus - VICE

Data and evidence – Launching the 2020 Culture and Health webinar Series – World Health Organization

WHO/Europe is pleased to release details of the 2020 Culture and Health webinar series. For the second year running, the series shines a spotlight on the cultural contexts of contemporary health challenges.

Featuring speakers from a variety of backgrounds including policy-makers, historians and people with lived experience the 2020 series will examine topics such as the rise of vaccine hesitancy, the digital footprint on health equity, the homecoming of traditional childbirth, and the mental health and well-being of youth in the Sustainable Development Goals (SDGs) era.

In addition to having a live audience, each webinar will be webcast and participants will be invited to tune in online and ask questions in real time.

The series is a collaboration between WHOs Cultural Contexts of Health and Well-being (CCH) project, the Centre for Global Health Histories at University of York, and the Wellcome Centre for Culture and Environments of Health at the University of Exeter. The Culture and Health webinar series is generously supported by the Wellcome Trust.

Join us for the first webinar of the year: What works? Complementary and alternative medicines in the biomedical world.

The use of complementary and alternative medicines, such as acupuncture and chiropractic treatment, is growing rapidly. However, there are still many obstacles to their integration into standard health services. How do cultural differences, prejudices and the history of medicine play a role in these practices and their acceptance? And how do we draw the line between what works and what doesn't?

The webinar will take place at the University of York on Thursday, 6 February 2020 at 13:0014:00 CET (12:0013:00 GMT). To join the conversation and watch the event live, please visit the webinar page.

View original post here:

Data and evidence - Launching the 2020 Culture and Health webinar Series - World Health Organization

Deepak Chopra Has Mastered the Seven Spiritual Laws of Big Fit Success – GQ

Allow author Deepak Chopra to teach you the seven spiritual laws of big fit success:

The Law of Pure Sneaker Potentiality: let your loud sneakers do the talking. Don't force the rest of your fit to compete with them. Let them simply BE.

The Law of Giving: let a simple and harmonious outfitred trim on a jacket picking up the vivid splash of your red sneakersbe a present to the world

The Law of Karma: each accessory will generate a force of energy that returns to the entire outfit. Good glasses make for good fits.

The Law of Least Effort: let a statement staple, like a velvet, mandarin collar jacket, do most of the leg work.

The Law of Intention and Desire: make a list of clothes you want, but find ways to bring these ideas to fruition using the contents you already possess.

The Law of Detachment: Not every piece has to be a showstopper. Sometimes black pants are just what the alternative-medicine healer ordered.

The Law of Dharma: We get dressed to fulfill a purpose.

More here:

Deepak Chopra Has Mastered the Seven Spiritual Laws of Big Fit Success - GQ